Roundtable on Black in cancer research and oncology

So, for example, it started out typically in what we call lymphoma and leukemia. And most recently, we've had approvals, at least here in the United States, from the FDA, for two CAR-T cell therapies for multiple myeloma. The headlines are showing that this is the direction all blood and bone marrow cancers are heading, and we're very excited about it.

However, one thing we wanted to address, especially for this audience, is that as these new therapies emerge, we must ensure that no group of people is left behind.